FAST: new look at the febuxostat safety profile

被引:11
作者
Bardin, Thomas [1 ,2 ,3 ]
Richette, Pascal [1 ,2 ]
机构
[1] Hop Lariboisibre, APHP Paris Nord, Dept Rheumatol, F-75010 Paris, France
[2] Univ Paris, INSERM, UMR1132, Bioscar, F-75010 Paris, France
[3] Vien Gut Med Ctr, French Vietnamese Res Ctr Gout & Chron Dis, Ho Chi Minh City, Vietnam
关键词
D O I
10.1016/S0140-6736(20)32343-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1704 / 1705
页数:2
相关论文
共 5 条
[1]   The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial [J].
Becker, Michael A. ;
Schumacher, H. Ralph ;
Espinoza, Luis R. ;
Wells, Alvin F. ;
MacDonald, Patricia ;
Lloyd, Eric ;
Lademacher, Christopher .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (02)
[2]   Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial [J].
Mackenzie, Isla S. ;
Ford, Ian ;
Nuki, George ;
Hallas, Jesper ;
Hawkey, Christopher J. ;
Webster, John ;
Ralston, Stuart H. ;
Walters, Matthew ;
Robertson, Michele ;
De Caterina, Raffaele ;
Findlay, Evelyn ;
Perez-Ruiz, Fernando ;
McMurray, John J. V. ;
MacDonald, Thomas M. .
LANCET, 2020, 396 (10264) :1745-1757
[3]   Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality [J].
Perez Ruiz, Fernando ;
Richette, Pascal ;
Stack, Austin G. ;
Gurunath, Ravichandra Karra ;
Garcia de Yebenes, Ma Jesus ;
Carmona, Loreto .
RMD OPEN, 2019, 5 (02)
[4]  
U.S. Food and Drug Administration, 2019, FDA ADDS BOX WARN IN
[5]   Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout [J].
White, William B. ;
Saag, Kenneth G. ;
Becker, Michael A. ;
Borer, Jeffrey S. ;
Gorelick, Philip B. ;
Whelton, Andrew ;
Hunt, Barbara ;
Castillo, Majin ;
Gunawardhana, Lhanoo .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13) :1200-1210